The sale provides MacroGenics with significant non-dilutive capital to extend its cash runway and focus on its clinical pipeline. Monitor closing conditions (regulatory and landlord consents) and any updates on pipeline catalysts. The transaction removes a capital-intensive CDMO operation, improving operational focus and financial flexibility.
Price Chart
Executive Summary
MacroGenics entered into a definitive agreement to sell its GMP manufacturing operations (CDMO business) to Bora Pharmaceuticals for a $122.5 million upfront cash payment, subject to customary closing adjustments and up to $5 million in contingent milestones. The transaction, expected to close in Q3 2026, provides non-dilutive capital to fund the company's R&D pipeline while retaining manufacturing access via a supply agreement.
Key Financial Metrics
Key Facts
- Base purchase price of $122.5 million in cash at closing, subject to working capital and indebtedness adjustments.
- Up to $5 million in additional contingent payments based on manufacturing milestones through 2028.
- Transaction includes transfer of the Rockville, MD manufacturing facility (11,000L capacity) and Frederick, MD warehouse.
- Approximately 140 MacroGenics employees expected to be hired by Bora.
- Closing expected in the third quarter of 2026, subject to customary conditions including landlord consents and regulatory approvals.
- MacroGenics will enter into a manufacturing and supply agreement with Bora for clinical and commercial supply post-closing.
- Transaction approved by both companies' boards of directors.
Financial Impact
Upfront cash consideration of $122.5 million, equating to ~65% of MacroGenics' pre-announcement market cap of $188 million. Potential additional $5 million in contingent payments.
Risk Factors
- Risk that closing conditions (including required consents) may not be satisfied, delaying or preventing the transaction.
- Potential for lower-than-expected net proceeds after transaction fees and working capital adjustments.
- Contingent earnout may not be realized, capping additional upside at $5 million.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001125345-26-000035 |
| Exhibit: exhibit991_pressrelease.htm | 0001125345-26-000035 |
| Document: mgnx-20260511.htm | 0001125345-26-000035 |
| Document: 0001125345-26-000035-index-headers.html | 0001125345-26-000035 |
| Document: 0001125345-26-000035-index.html | 0001125345-26-000035 |
| Document: 0001125345-26-000035.txt | 0001125345-26-000035 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 8, 2026 12w ago | 8-K | $4.57 $4.01 | ▼ −12.25% | ▼ −14.50% | $3.58 (−21.66%) |
Jul 2, 2026 13w ago | Press Release | $4.71 $3.78 | ▼ −19.75% | ▼ −19.33% | $3.58 (−23.99%) |
Jun 12, 2026 16w ago | Institutional Cluster | $3.96 $4.33 | ▲ +9.34% | ▲ +7.56% | $3.58 (−9.60%) |
Jun 11, 2026 16w ago | Institutional Cluster | $4.01 $4.57 | ▲ +13.97% | ▲ +12.07% | $3.58 (−10.72%) |
May 13, 2026 20w ago | 8-K | $4.16 $3.96 | ▼ −4.81% | ▼ −3.95% | $3.58 (−13.94%) |
May 12, 2026 20w ago | 8-K | $3.52 $3.87 | ▲ +9.94% | ▲ +11.67% | $3.58 (+1.70%) |
May 11, 2026 20w ago | Press Release | $3.52 $3.87 | ▲ +9.94% | ▲ +11.67% | $3.58 (+1.70%) |
Apr 8, 2026 25w ago | 8-K | $3.44 $3.01 | ▼ −12.50% | ▼ −20.07% | $3.58 (+4.07%) |
Apr 8, 2026 25w ago | Press Release | $3.44 $3.01 | ▼ −12.50% | ▼ −20.07% | $3.58 (+4.07%) |
Apr 8, 2026 25w ago | DEFA14A | $3.44 $3.01 | ▼ −12.50% | ▼ −20.07% | $3.58 (+4.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access